echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Ann Rheum Dis: Effects of the new definition of ACC/AHA hypertension on systemic lupus atherosclerotic vascular events

    Ann Rheum Dis: Effects of the new definition of ACC/AHA hypertension on systemic lupus atherosclerotic vascular events

    • Last Update: 2020-05-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The 2017 American College of Cardiology/American Heart Association guidelines define hypertension as 130/80mmHgStudies of patients with connective tissue disease were not taken into accountThe purpose of the study was to assess the effect of this definition on systemic lupus erythematosus atherosclerosis vascular events (AVEs)divided patients from the Toronto Lupus Clinic with at least 2 years of follow-up and no AVE for at least 2 years (Follow-up to the first appearance of AVE (fatal or non-fatal coronary disease, cerebrovascular events and peripheral vascular disease) or the last visitThe groups were compared according to baseline atherosclerosis risk factorsConduct a multi-factor time-dependent analysis to adjust for other risk factors that exist1532 patients who met the criteria, 155 (10.1%) had blood pressure of 140/90mmHg, 316 (20.6%) had blood pressure of 130-139/80-89mmHg, and 1061 (69.3%) had normal blood pressureAfter an average follow-up of 10.8 years, 124 AVEs were recordedThe incidence of the three groups was 18.9, 11.5 and 4.5 per 1000 patients per year (130-139/80-89mmHg group and normal blood pressure group p-0.0007)The average blood pressure of 130-139/80-89mmHg for the first two years was independently associated with the occurrence of AVEs (HR 1.73, 95% CI 1.13-2.65, p-0.011)the incidence of AVEs in 130-139/80-89mmHg increased in patients with lupus within 2 years compared to patients with normal blood pressureThis blood pressure level should be targeted for antihypertensive therapy to minimize its cardiovascular risk
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.